AR041722A1 - Formulaciones de liberacion prolongada inyectables - Google Patents

Formulaciones de liberacion prolongada inyectables

Info

Publication number
AR041722A1
AR041722A1 ARP030103894A ARP030103894A AR041722A1 AR 041722 A1 AR041722 A1 AR 041722A1 AR P030103894 A ARP030103894 A AR P030103894A AR P030103894 A ARP030103894 A AR P030103894A AR 041722 A1 AR041722 A1 AR 041722A1
Authority
AR
Argentina
Prior art keywords
prolonged release
release formulations
injectable prolonged
injectable
viscous
Prior art date
Application number
ARP030103894A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR041722A1 publication Critical patent/AR041722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporciona una formulación de liberación prolongada inyectable que es viscosa, o que se hace viscosa in situ, que comprende un compuesto farmacéutico arilheterocíclico solubilizado con ciclodextrina, como por ejemplo ziprasidona, para el tratamiento de un tarstorno psicótico, por ejemplo esquizofrenia. Formulaciones de liberación prolongada inyectables.
ARP030103894A 2002-10-25 2003-10-24 Formulaciones de liberacion prolongada inyectables AR041722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
AR041722A1 true AR041722A1 (es) 2005-05-26

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103894A AR041722A1 (es) 2002-10-25 2003-10-24 Formulaciones de liberacion prolongada inyectables

Country Status (20)

Country Link
US (1) US20040138237A1 (es)
EP (1) EP1575616A2 (es)
JP (1) JP2006514923A (es)
KR (1) KR20050055781A (es)
CN (1) CN1849110A (es)
AR (1) AR041722A1 (es)
AU (1) AU2003267788A1 (es)
BR (1) BR0315568A (es)
CA (1) CA2503076A1 (es)
MX (1) MXPA05002561A (es)
NL (1) NL1024590C2 (es)
NO (1) NO20052463L (es)
PA (1) PA8586201A1 (es)
PE (1) PE20040499A1 (es)
PL (1) PL377679A1 (es)
RU (1) RU2310450C2 (es)
TW (1) TW200423941A (es)
UY (1) UY28038A1 (es)
WO (1) WO2004037289A2 (es)
ZA (1) ZA200501921B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
US20080193542A1 (en) * 2005-04-13 2008-08-14 Pfizer Inc. Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US20110144202A1 (en) * 2008-06-16 2011-06-16 Uwe Marx Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US10799289B2 (en) 2018-10-15 2020-10-13 Avent, Inc. Compositions, systems, kits, and methods for neural ablation
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
CZ20014230A3 (cs) * 1999-05-27 2002-08-14 Pfizer Products Inc. Suspense ziprasidonu
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
US20040138237A1 (en) 2004-07-15
PE20040499A1 (es) 2004-08-18
NL1024590C2 (nl) 2005-05-23
WO2004037289A2 (en) 2004-05-06
RU2005112207A (ru) 2005-09-10
TW200423941A (en) 2004-11-16
PA8586201A1 (es) 2004-09-16
EP1575616A2 (en) 2005-09-21
BR0315568A (pt) 2005-08-23
NO20052463L (no) 2005-05-23
MXPA05002561A (es) 2005-05-05
NL1024590A1 (nl) 2004-04-27
CA2503076A1 (en) 2004-05-06
CN1849110A (zh) 2006-10-18
UY28038A1 (es) 2004-05-31
ZA200501921B (en) 2006-10-25
PL377679A1 (pl) 2006-02-06
RU2310450C2 (ru) 2007-11-20
WO2004037289A3 (en) 2005-12-01
KR20050055781A (ko) 2005-06-13
AU2003267788A1 (en) 2004-05-13
JP2006514923A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
AR041722A1 (es) Formulaciones de liberacion prolongada inyectables
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
ECSP077348A (es) Composiciones de amitraz
BRPI0516059A (pt) pelìcula proterora de piso, método para aplicar uma pelìcula ao piso, e, piso
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
BR0307066A (pt) Dispositivo médico resistente a infecção
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
BR0116332A (pt) Processo para o aumento da estabilidade
AR053571A1 (es) Prevencion de infeccion por vih
GT200500349A (es) Formulaciones de benzoxazoles substituidos
BRPI0416311A (pt) composição, uso de uma composição e processo para melhorar a penetração de um agente ativo farmacêutico
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
AR075082A1 (es) Utilizacion de vitamina e o sus derivados para el control de artropodos
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
GT200300064A (es) Formulacion farmaceutica que comprende melatonina
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
PA8661101A1 (es) Compuestos antihelminticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal